Immutep Receives Regulatory Clearance For Phase I Study Of First-In-Class LAG-3 Agonist Antibody Designed To Treat Autoimmune Diseases
Portfolio Pulse from Benzinga Newsdesk
Immutep Limited has received regulatory clearance to initiate a Phase I study of its first-in-class LAG-3 agonist antibody, IMP761, designed to treat autoimmune diseases. The study is expected to enroll its first participants in Q3 2024.
July 17, 2024 | 12:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Immutep Limited has received regulatory clearance to start a Phase I study of IMP761, a novel LAG-3 agonist antibody for autoimmune diseases. This regulatory milestone is a significant step forward for the company.
The regulatory clearance for the Phase I study of IMP761 is a significant milestone for Immutep, indicating progress in their pipeline and potential future revenue from successful development. This news is likely to positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100